CVS Health Corp vs Monster Beverage Corp — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while Monster Beverage Corp trades at $43.64 (market cap $85.51B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays a 3.03% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Monster Beverage Corp for 72 Days on average.
| CVS | MNST | |
|---|---|---|
Market Cap | $112.29B | $85.51B |
Volume | 7,763,676 | 8,569,709 |
Sector | Health | Consumer Staples |
52-Week High | $110.60 | $49.97 |
52-Week Low | $70.08 | $33.16 |
Typical Hold Time | 83 Days | 72 Days |
Enterprise Value | $174.64B | $83.81B |
Dividend Yield | 3.03% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, down 0.17% on the day, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07B in 2025, though net income margin compressed to 1.18%. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.
CVS presents a mixed outlook with solid revenue growth and analyst bullishness (85% buy ratings, $111.20 consensus target) offset by profitability pressures and a bearish technical trend. Key risks include reimbursement pressure and ongoing legal investigations, but the stock offers value with a low P/S of 0.27 and dividend yield support.
Monster Beverage (MNST) trades at $43.65, up 1.8% with bullish technical signals and strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $0.30 exceeding expectations. Revenue growth accelerated to $8.29B in 2025 with impressive 23.08% net margins. Analyst consensus is bullish with 52% buy ratings and $98.22 price target, representing 125% upside potential. Recent 1:2 stock split on August 11, 2026, enhances accessibility while maintaining zero long-term debt.
MNST presents compelling growth prospects with international expansion driving 35% sales surge and clean balance sheet. However, elevated valuation multiples (P/E 40.42) and regulatory challenges in key markets like India pose risks. The stock's technical strength and fundamental momentum support continued upside, though investors should monitor margin pressures from inflation and competitive dynamics in the energy drink sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →